Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders

Abstract

A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.

1 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use in the treatment of patients suffering from fibrosis and/or fibrotic disorders. 
     
     
         2 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 , wherein the organs affected by said fibrosis and/or fibrotic disorders are selected from the group consisting of lung, liver, kidney, cardiovascular system or skin. 
     
     
         3 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 ,
 wherein said fibrotic disorder affects one or more organs selected from the group consisting of lung, liver, kidney, heart and skin. 
 
     
     
         4 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 ,
 wherein said fibrotic disorder comprises or is systemic sclerosis (SSc). 
 
     
     
         5 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use in the treatment of patients suffering from systemic sclerosis (SSc). 
     
     
         6 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 4 ,
 wherein the systemic sclerosis comprises systemic sclerosis of the lung, liver, kidney, cardiovascular system or skin. 
 
     
     
         7 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to of  claim 4 ,
 wherein the systemic sclerosis affects one or more organs selected from the group consisting of lung, liver, kidney, heart and skin. 
 
     
     
         8 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 4 , wherein the systemic sclerosis affects the cardiovascular system, the blood vessels and/or the blood. 
     
     
         9 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 , wherein the fibrotic disorder and/or the systemic sclerosis comprises one or more indications selected from the group consisting of idiopathic pulmonary fibrosis, primary sclerosing cholangitis, non-alcoholic steatohepatitis (NASH), primary focal glomerulosclerosis, primary segmental glomerulosclerosis, diabetic nephropathy, diastolic dysfunction and myelofibrosis. 
     
     
         10 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 , wherein said fibrotic disorder and/or systemic sclerosis comprises pulmonary fibrosis and/or alveolitis (interstitial lung disease, ILD). 
     
     
         11 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 , wherein the disease to be treated is systemic sclerosis of the lung and/or skin. 
     
     
         12 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 11 , wherein the systemic sclerosis of the skin is diffuse cutaneous systemic sclerosis (dcSSc) or limited cutaneous systemic sclerosis (lcSSc). 
     
     
         13 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use in the treatment of pulmonary fibrosis, alveolitis (interstitial lung disease, ILD), and/or sclerodermal interstitial lung disease (SSc-ILD). 
     
     
         14 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 , wherein said treatment comprises the administration of a dose, preferably an effective dose, of said antibody, or biologically active variant or modification thereof, in an amount of 500 mg-3000 mg per month. 
     
     
         15 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 , wherein said treatment comprises the administration of a dose, preferably an effective dose, of said antibody, or biologically active variant or modification thereof, in an amount of 1000 mg-2000 mg per month. 
     
     
         16 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 14 , wherein the dose, preferably the effective dose, is administered in a single dose. 
     
     
         17 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 , wherein said treatment comprises the administration of said antibody, or biologically active variant or modification thereof, in an amount of about 500 mg per month, about 1000 mg per month, about 1500 mg per month, about 2000 mg per month or about 2500 mg per month. 
     
     
         18 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 17 , wherein said amount is administered in a single dose. 
     
     
         19 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 , wherein said antibody or said biologically active variant or modification thereof is administered as monotherapy. 
     
     
         20 : The anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 ,
 wherein said biological active variant or modification comprises the CDR regions and heavy and light chain variable regions of DI17E6, which are at least 80% identical, at least 90% identical, at least 95% identical, at least 98% identical, or at least 99% identical in amino acid sequence compared to the variable regions of DI17E6. 
 
     
     
         21 - 46 . (canceled)